Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 189,600 shares, an increase of 183.8% from the March 31st total of 66,800 shares. Based on an average daily trading volume, of 2,030,000 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH initiated coverage on Biodexa Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $8.00 price target for the company.

Biodexa Pharmaceuticals Stock Up 79.4 %

Shares of BDRX stock traded up $0.58 on Friday, reaching $1.30. The stock had a trading volume of 70,155,596 shares, compared to its average volume of 311,676. Biodexa Pharmaceuticals has a 12 month low of $0.67 and a 12 month high of $21.38. The firm’s 50-day moving average is $1.16 and its two-hundred day moving average is $2.20.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.